Zoetis

YTD

ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments.

CEO

Kristin C. Peck

CEOKristin C. Peck

Employees

13,800

Employees13,800

Headquarters

Parsippany, New Jersey

HeadquartersParsippany, New Jersey

Founded

1952

Founded1952

Employees

13,800

Employees13,800

ZTS Key Statistics

Market cap

53.72B

Market cap53.72B

Price-Earnings ratio

20.54

Price-Earnings ratio20.54

Dividend yield

1.64%

Dividend yield1.64%

Average volume

4.71M

Average volume4.71M

High today

—

High today—

Low today

—

Low today—

Open price

$124.34

Open price$124.34

Volume

119.00

Volume119.00

52 Week high

$177.40

52 Week high$177.40

52 Week low

$115.25

52 Week low$115.25

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $122.05. The company's market cap stands at 53.72B, with a P/E ratio of 20.54 and a dividend yield of 1.6%.

On 2026-01-29, Zoetis(ZTS) shares started trading at $124.34, with intraday highs of — and lows of —.

Trading volume for Zoetis(ZTS) stock has reached 119, versus its average volume of 4.71M.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $177.40 and a low of $115.25.

ZTS News

Simply Wall St 4d

A Look At Zoetis Valuation After Analyst Downgrades And Softer Guidance

Multiple analyst downgrades following Zoetis (ZTS) flat revenue quarter and slightly softer full year guidance have pushed the stock under closer scrutiny, as c...

Simply Wall St 6d

How Soft Guidance And Innovation Concerns At Zoetis Have Changed Its Investment Story

In recent months, Zoetis reported quarterly revenues of about US$2.40 billion that were flat year on year, alongside full-year guidance that came in slightly be...

Simply Wall St 7d

Zoetis Debuts Lenivia And Portela As OA Safety Story Evolves

Zoetis (NYSE:ZTS) has launched new next generation osteoarthritis treatments, Lenivia and Portela. The products are designed to address safety concerns linked...

Analyst ratings

68%

of 22 ratings

Buy

68.2%

Hold

31.8%

Sell

More ZTS News

Nasdaq 7d

This Could Be One of the Best Healthcare Stock Buying Opportunities I've Seen in Years

Key Points Shares of Zoetis easily outpaced the S&P 500 for over a decade before they turned south. The stock is down nearly 40% over the last few years -- ye...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.